Patents Assigned to Ribovax Biotechnologies SA
  • Patent number: 7811973
    Abstract: The present invention provides novel technologies for producing and screening fusion proteins on the surface of filamentous phage. In particular, a single vector can be used for generating cell and phage libraries containing a given series of protein sequences fused to either one or other of two phage coat proteins. This approach simplifies and improves the efficiency of the subsequent phage display-based selection of protein-binding molecules having therapeutic or diagnostic utility, such as antibodies, peptides, or epitope-binding regions.
    Type: Grant
    Filed: July 6, 2006
    Date of Patent: October 12, 2010
    Assignee: Ribovax Biotechnologies SA
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20100074906
    Abstract: The present invention provides novel antibody sequences that bind Varicella Zoster Virus (VZV) and neutralize VZV infection. The novel sequences can be used for the medical management of VZV infection, in particular for detecting the virus or for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of VZV infection.
    Type: Application
    Filed: February 6, 2008
    Publication date: March 25, 2010
    Applicant: RIBOVAX BIOTECHNOLOGIES SA
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20100040602
    Abstract: The present invention provides novel antibody sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections.
    Type: Application
    Filed: December 12, 2007
    Publication date: February 18, 2010
    Applicant: RIBOVAX BIOTECHNOLOGIES SA
    Inventors: Ada Funaro, Giorgio Gribaudo, Santo Landolfo
  • Publication number: 20100028907
    Abstract: The present invention provides novel human protein antigens and related antibodies that have been identified as being specifically expressed in association to human Pancreatic Ductal Adenocarcinoma (PDA). In particular, novel phosphorylated isoforms of alpha-enolase have been identified in transformed cell lines of pancreatic origin and antibodies binding such isoforms are specifically present in the sera of PDA patients. These proteins and antibodies can be useful for the diagnosis and the treatment of PDA and other cancers having common molecular features.
    Type: Application
    Filed: September 28, 2007
    Publication date: February 4, 2010
    Applicants: Ribovax Biotechnologies SA, Bioline Diagnostici SRL
    Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
  • Publication number: 20090270268
    Abstract: The present Invention provides novel methods for immortalizing cells that secrete antibodies of one or more specific isotypes. Polyclonal, oligoclonal, and monoclonal populations of cells obtained using the methods of the Invention can be screened on the basis of the functional and/or binding activities of the antibodies they secrete, for example directed to antigens of human or viral origin having medical interest, in cell culture conditions. Using these methods, human B cells that secrete antibodies binding human Cytomegalovirus, Herpes Simplex Virus, or HSP60 protein have been efficiently immortalized with Epstein-Barr virus.
    Type: Application
    Filed: December 15, 2006
    Publication date: October 29, 2009
    Applicant: RIBOVAX BIOTECHNOLOGIES SA
    Inventors: Ada Funaro, Gianni Garotta, Marianne Murphy